| Total | Chronic phase CML | Accelerated phase CML |
---|---|---|---|
Patient number | 165 | 127 | 38 |
Treatment duration (mo.), median (range) | 30.7 (1.2–58.6) | 34.5 (1.2–57.5) | 25.5 (1.4–58.6) |
Ongoing, n (%) | 114 (69.1) | 96 (75.6) | 18 (47.4) |
Olverembatinib 20Â mg | 11 (9.6) | 8 (8.3) | 3 (16.7) |
Olverembatinib 30Â mg | 44 (38.6) | 38 (39.6) | 6 (33.3) |
Olverembatinib 40Â mg | 48 (42.1) | 41 (42.7) | 7 (38.9) |
Olverembatinib 50Â mg | 11 (9.6) | 9 (9.4) | 2 (11.1) |
Discontinuation, n (%) | 51 (30.9) | 31 (24.4) | 20 (52.6) |
Disease progression | 15 (9.1) | 5 (3.9) | 10 (26.3) |
Adverse events | 13 (7.9) | 9 (7.1) | 4 (10.5) |
Treatment failure | 12 (7.2) | 8 (6.3) | 4 (10.5) |
Withdrawal by subject | 8 (4.8) | 8 (6.3) | 0 |
Death | 3 (1.8) | 1 (0.8) | 2 (5.3) |